Poster Session C
Spondyloarthritis (SpA) including psoriatic arthritis (PsA)
Arthur Kavanaugh, MD
UCSD
La Jolla, California, United States
No financial relationships with ineligible companies to disclose
Treatment with zasocitinib did not appear to result in laboratory parameter changes reported in studies of JAK1/2/3 inhibitors. Further larger phase 3 studies in patients with active PsA are planned to confirm these observations.
References
1. Kivitz A et al. Arthritis Rheumatol. 2023; 75 (suppl 9).
A. Kavanaugh: AbbVie, 2, Amgen, 2, BMS, 2, Janssen, 2, MoonLake Immunotherapeutics, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB, 2, 5; E. Muensterman: Takeda, 3, 11; A. Lertratanakul: Takeda, 3, 11; T. Hong: Takeda, 3, 11; J. Chen: Takeda, 3, 11; P. Pothula: Takeda, 3, 11; E. Mark: Takeda, 3, 11; A. Kivitz: AbbVie, 2, 6, Amgen, 6, 11, Coval, 2, Ecor1, 2, Fresenius Kabi, 2, Genzyme, 12, Scientific ExpertGenzyme, Gilead, 2, 11, GlaxoSmithKlein (GSK), 2, 6, 11, Grunenthal, 2, Horizon, 2, Innovaderm, 2, Janssen, 2, Lilly, 6, Novartis, 11, Pfizer, 6, 11, Prime, 12, Educational, Prometheus, 2, Sanofi - Regeneron, 6, SynAct, 2, Takeda, 2, UCB, 2, 6, XBiotech, 2.